Drug Profile
Research programme: HSP 90 inhibitors - Pharmascience
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aegera Therapeutics
- Class Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation; Mycoses; Neurodegenerative disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Canada